- Home
- TACH vs LXEO Comparison
TACH vs LXEO Comparison
Compare TACH & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Company Overview
Basic Information| Metric | TACH | LXEO |
|---|---|---|
| Founded | 2024 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.1M | 396.5M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | TACH | LXEO |
|---|---|---|
| Price | $10.43 | $4.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.44 |
| AVG Volume (30 Days) | 95.5K | ★ 932.3K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $39.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.10 | $3.99 |
| 52 Week High | $10.59 | $10.99 |
Technical Indicators
Market Signals| Indicator | TACH | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 54.26 | 49.48 |
| Support Level | $10.28 | $4.39 |
| Resistance Level | $10.48 | $5.36 |
| Average True Range (ATR) | 0.01 | 0.29 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 31.58 | 55.01 |
Price Performance
Historical Comparison TACH
LXEO
About TACH Titan Acquisition Corp. Class A Ordinary Shares
Titan Acquisition Corp is a blank check company.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.